BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8105974)

  • 1. High-dose therapy for lymphoma.
    Shepherd JD; Phillips GL
    Curr Opin Oncol; 1993 Sep; 5(5):797-804. PubMed ID: 8105974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
    Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma.
    Bolwell BJ
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):86-95. PubMed ID: 7916488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow transplantation for non-Hodgkin's lymphoma: a review.
    Salzman DE; Briggs AD; Vaughan WP
    Am J Med Sci; 1997 Apr; 313(4):228-35. PubMed ID: 9099153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy and autografting with peripheral blood stem cells in malignant lymphoma: granulocyte-macrophage colony-stimulating factor for stem cell mobilization.
    Haas R; Hohaus S; Goldschmidt H; Möhle R; Witt B; Wannenmacher M; Hunstein W
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):19-24. PubMed ID: 7801144
    [No Abstract]   [Full Text] [Related]  

  • 7. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
    Advani R; Chao NJ; Horning SJ; Blume KG; Ahn DK; Lamborn KR; Fleming NC; Bonnem EM; Greenberg PL
    Ann Intern Med; 1992 Feb; 116(3):183-9. PubMed ID: 1345803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
    Fay JW; Bernstein SH
    Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hematopoietic stem cell transplantation for malignant lymphoma].
    Asaoku H
    Nihon Rinsho; 2000 Mar; 58(3):704-8. PubMed ID: 10741150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
    Knauf WU; Koenigsmann MP; Notter M; Hoppe B; Reufi B; Oberberg D; Thiel E; Berdel WE
    Leuk Lymphoma; 1996 Oct; 23(3-4):305-11. PubMed ID: 9031111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
    J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
    Bennett CL; Armitage JL; Armitage GO; Vose JM; Bierman PJ; Armitage JO; Anderson JR
    J Clin Oncol; 1995 Apr; 13(4):969-73. PubMed ID: 7707125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
    Kessinger A; Nademanee A; Forman SJ; Armitage JO
    Hematol Oncol Clin North Am; 1990 Jun; 4(3):577-87. PubMed ID: 1972701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
    De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
    Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma.
    Vose JM; Armitage JO
    Hematol Oncol Clin North Am; 1993 Jun; 7(3):577-90. PubMed ID: 8102135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autologous bone marrow transplantation in children with acute leukemia or non-Hodgkin's lymphoma].
    Emminger W; Hinterberger W; Emminger-Schmidmeier W; Peters C; Fink FM; Zoubek A; Haas OA; Höcker P; Hawliczek R; Knapp W
    Wien Med Wochenschr; 1991; 141(9-10):225-8. PubMed ID: 1683071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.